ATRA - Atara Biotherapeutics, Inc.
| Previous Close | 15.99 |
| Open | 16.03 |
| Bid | 10.19 x 1000 |
| Ask | 16.25 x 1100 |
| Day's Range | 15.31 - 16.15 |
| 52 Week Range | 10.38 - 41.97 |
| Volume | 419,214 |
| Avg. Volume | 685,838 |
| Market Cap | 837M |
| Beta (5Y Monthly) | 2.03 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -6.05 |
| Earnings Date | Nov 7, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 29.13 |
- Insider Monkey
Hedge Funds Have Never Been More Bullish On Atara Biotherapeutics Inc (ATRA)
"The global economic environment is very favorable for investors. Economies are generally strong, but not too strong. Employment levels are among the strongest for many decades. Interest rates are paused at very low levels, and the risk of significant increases in the medium term seems low. Financing for transactions is freely available to good borrowers, […]
- GuruFocus.com
Seth Klarman Pares Paratek Pharmaceuticals Stake
Renowned guru slims position in struggling biotech that focuses on infectious diseases Continue reading...
- GlobeNewswire
Atara Biotherapeutics Reports Updated Long-Term Clinical Results from a Tab-cel® Multicenter Expanded Access Protocol (EAP) Study for Patients with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) at the 61st American Society of Hematology (ASH) Annual Meeting
61 patients with diverse EBV-associated diseases, including 26 relapsed/refractory EBV+ PTLD patients were treated in a multicenter tab-cel® (tabelecleucel) EAP study Tab-cel®.
- GlobeNewswire
Atara Biotherapeutics to Participate at Evercore ISI Second Annual HealthCONx Conference
SOUTH SAN FRANCISCO, Calif., Nov. 26, 2019 -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel.
- Zacks
Atara Biotherapeutics (ATRA) Upgraded to Buy: Here's Why
Atara Biotherapeutics (ATRA) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Thomson Reuters StreetEvents
Edited Transcript of ATRA earnings conference call or presentation 7-Nov-19 1:00pm GMT
Q3 2019 Atara Biotherapeutics Inc Earnings Call
- GlobeNewswire
Atara Biotherapeutics Announces Third Quarter 2019 Financial Results and Recent Clinical, Operational and Strategic Progress
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2019 -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel.
- GlobeNewswire
Atara Biotherapeutics to Present Tab-cel® Long-Term Clinical Outcomes from a Multicenter Expanded Access Protocol (EAP) Study for Patients with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) at the 61st American Society of Hematology (ASH) Annual Meeting
26 relapsed/refractory EBV+ PTLD patients were treated in a multicenter tab-cel® EAP study including a subgroup of 22 patients who would have likely met eligibility criteria for.
- GlobeNewswire
Atara Biotherapeutics to Announce Third Quarter 2019 Operational Progress and Financial Results on Thursday, November 7, 2019
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2019 -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel.
- Insider Monkey
Did Hedge Funds Drop The Ball On Atara Biotherapeutics Inc (ATRA)?
Investing in small cap stocks has historically been a way to outperform the market, as small cap companies typically grow faster on average than the blue chips. That outperformance comes with a price, however, as there are occasional periods of higher volatility. The last 12 months is one of those periods, as the Russell 2000 […]
- GlobeNewswire
Atara Biotherapeutics Announces Executive Departures
Atara Biotherapeutics, Inc. (ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced the departures of Dr. Christopher Haqq, Chief Scientific Officer, and Mina Kim, General Counsel and Head of Corporate Strategy. “I want to thank Chris and Mina for their significant contributions to Atara,” said Pascal Touchon, President and Chief Executive Officer of Atara Biotherapeutics.
- Schaeffer's Investment Research
ATRA Stock Hits Five-Year Low on Goldman Bear Note
The analyst thinks Atara Biotherapeutics stock could sink 34%
- Barrons.com
Atara Biotherapeutics Stock Falls After Goldman Downgrade
(GS) has lost confidence in (ATRA) downgrading the stock to Sell from Neutral on Friday. Shares of the clinical-stage immunotherapy company were down 5.3%, after a 5% drop on Thursday. Goldman’s Salveen Richter cited “a lack of near-term catalysts and questions surrounding the clinical programs” as the reasons for her call.
- Simply Wall St.
Is Atara Biotherapeutics (NASDAQ:ATRA) In A Good Position To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
- GuruFocus.com
Seth Klarman Further Increases Translate Bio Stake
Baupost leader ups bet on biotech company that focuses on genetic diseases Continue reading...
- TipRanks
3 Biotech Stocks Surging on Positive Results
It’s no question that the biotech space is booming. According to Global Market Insights, the global biotech market is expected to reach $775 billion by 2024, up from $399.4 billion in 2017. While they tend to be more volatile, biotech stocks can offer substantial upside given the fact that a single positive catalyst can send shares soaring. For a few biotechs, positive trial results might just be that catalyst. Wall Street analysts have pinpointed 3 biotech stocks that have seen share prices rise recently in response to new positive data. Each of these stocks has garnered support from the rest of the Street with a “Strong Buy” analyst consensus. This consensus is generated using the last three months’ worth of ratings from all other analysts.With investors on average allocating 2%-6% of their portfolios to these biotechs based on TipRanks Smart Portfolio users, we wanted to learn more about the 3 stocks highlighted by analysts. Should you invest now? Here’s the low-down. Moderna Inc.Moderna (MRNA\- Get Report) uses messenger RNA (mRNA), or molecules that transfer the instructions needed to make proteins located in DNA, to tell patients’ own cells to create proteins to treat, cure or even prevent diseases such as cancer, cardiovascular disease, infectious diseases as well as other rare diseases. Since its September 12 announcement that its Phase 1 Cytomegalovirus (CMV) and Chikungunya programs demonstrated promising results, shares jumped 10% higher. CMV affects one in 150 newborns and can cause jaundice, poor liver function, microencephaly, pneumonia and several other symptoms. Chikungunya is spread through mosquito bites with symptoms including fever and joint pain. According to Needham’s Alan Carr, the CMV vaccine represented a “potent vaccine and compares favorably to the that of the Merck V160 attenuated vaccine”. Adding to the good news, management stated that it expects rapid progression through a Phase 2 trial to a single registration trial to test the vaccine’s ability to prevent the spread of infection from pregnant women to their babies. As there currently aren’t any treatments or vaccines for CMV, these results are an important milestone for MRNA. In addition, its Chikungunya vaccine looks solid as it demonstrated antibody production similar to that of its preclinical program in non-human primates. The analyst believes this could translate to other programs in earlier stage development including methylmalonic acidemia (MMA), which Carr deems the “next clinical catalyst for the stock”. “Both sets of data represent an important step forward for the company,” he explained. The three-star analyst also cites its ongoing immuno-oncology programs for melanoma and ovarian cancer as important areas to watch. All of this lends itself to his conclusion that MRNA could see massive gains. As a result, he reiterated his Buy rating and $28 price target on September 13. He sees 55% upside potential for MRNA.Wall Street appears to be on the same page. MRNA boasts significant support from the Street as it has only received Buy ratings in the last three months, giving it a ‘Strong Buy’ analyst consensus. Its $33 average price target indicates 80% upside potential. Cytokinetics Inc. Cytokinetics (CYTK\- Get Report) wants to use muscle activators to improve the muscle function in patients suffering from cardiovascular disease and neuromuscular diseases. While shares dipped 1% on September 20, the company has achieved 106% growth year-to-date. On top of its already impressive year-to-date gain, CYTK shares have surged 5% in the last five days after it announced data from the Phase 1 study of its CK-274 drug in healthy patients at the annual Heart Failure Society of America (HFSA) meeting. The results suggested that the drug was well-tolerated and met safety requirements. Based on the data, the company can move forward with its Phase 2 clinical trial to treat patients with obstructive hypertrophic cardiomyopathy (HCM), an inherited condition that causes part of the heart to get thicker affecting its ability to pump blood.Its competitor MyoKardia’s (MYOK) mavacamten drug has already gone through a Phase 2 trial, but it should be noted that CYTK’s drug offers a shorter half life as well as a shallower dose response relationship, which is good news for CYTK. With CYTK expected to start the Phase 2 trial by the end of 2019, Needham analyst Chad Messer takes a bullish stance on the biotech. As a result, he reiterated his Buy rating and $16 price target on September 16. His price target only suggests 23% upside potential as it doesn’t include the recent findings. The four-star analyst only factored in its omecamtiv mecarbil drug, which was created from a collaboration with Amgen (AMGN), into CYTK’s price target as this drug has already gone through seven Phase 2 clinical trials. He deems CYTK’s early pipeline as strictly upside. Wall Street sees even more potential when it comes to CYTK. With 5 Buy ratings vs 1 Hold received in the last three months, CYTK has a ‘Strong Buy’ analyst consensus. In general, the Street forecasts 55% upside based on the $20 average price target. Atara BiotherapeuticsThe last biotech stock on our list has developed an allogenic T-cell immunotherapy to target cancerous or diseased cells rather than healthy cells. Atara (ATRA\- Get Report) hopes to use this treatment for patients with cancer, autoimmune diseases as well as viral diseases. While its 54% year-to-date decline is alarming, some analysts point to its 4% climb since it reported new data on September 13 as a step in the right direction. On September 13, ATRA announced initial efficacy data and new safety data from its ongoing Phase 1 study of its ATA188 drug at the Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). The drug was designed to treat patients with multiple sclerosis (MS), a chronic neurological autoimmune disease that can cause vision problems and muscle weakness.ATA188 targets B cells infected with Epstein-Barr Virus (EBV) which is thought to play a role in the development of MS. The results demonstrated a favorable safety profile as well as significant efficacy, with its second cohort exhibiting clinical improvement. These results combined with its completion of the fourth and final Phase 1 dose escalation cohort could be a potential catalyst for the company as MS affects more than two million people globally.While Roth Capital analyst Anthony Butler notes that he would have liked to see more granular data, he believes the results are promising. Following this development, the four-star analyst reiterated his Buy rating and $30 price target on September 13. The price target reflects his confidence in ATRA's ability to gain 90% over the next twelve months.The rest of the Street is just as bullish. ATRA boasts a ‘Strong Buy’ analyst consensus and a $35 average price target, implying 119% upside potential. Find analysts’ favorite stocks with the Top Analysts’ Stocks tool
- Benzinga
The Daily Biotech Pulse: All Eyes On Aimmune, Ritter Stumbles In Late-Stage Study, Catalyst Shelves Offering Plans
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 11) Ardelyx Inc (NASDAQ: ARDX ) Avedro Inc (NASDAQ: AVDR ...
- GlobeNewswire
Atara Biotherapeutics Reports Early Findings of Potential Efficacy from Phase 1 Study of ATA188 in Patients with Progressive Multiple Sclerosis at ECTRIMS 2019
Atara Biotherapeutics, Inc. (ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced the presentation of initial efficacy data as well as updated safety results from its ongoing Phase 1 study of ATA188 for the treatment of progressive forms of multiple sclerosis (MS). The data are featured in a late-breaking poster presentation at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), held in Stockholm, Sweden, September 11-13, 2019.
- GuruFocus.com
3 Small-Cap Stock Picks From Seth Klarman
The guru has high conviction in these stocks Continue reading...
- GuruFocus.com
Baupost's Seth Klarman Dives Further Into Translate Bio
Guru adds to position in biotech company that focuses on genetic diseases Continue reading...
- GlobeNewswire
Atara Biotherapeutics to Present Initial Efficacy and Additional Safety Results from Phase 1 Study of ATA188 in Patients with Progressive Multiple Sclerosis at ECTRIMS 2019
Atara Biotherapeutics, Inc. (ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced it will present for the first time initial efficacy data as well as updated safety results from its ongoing Phase 1 study of ATA188 for the treatment of progressive forms of multiple sclerosis (MS) in a late-breaking poster presentation at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), September 11-13, 2019, in Stockholm, Sweden. ATA188 is an off-the-shelf, allogeneic T-cell immunotherapy that targets Epstein-Barr Virus (EBV)-infected B cells, which we believe play a fundamental role in the pathogenesis of MS.
- GlobeNewswire
Atara Biotherapeutics to Participate in Citi 14th Annual Biotech Conference
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel.
- Zacks
Are Options Traders Betting on a Big Move in Atara (ATRA) Stock?
Investors need to pay close attention to Atara (ATRA) stock based on the movements in the options market lately.
- Thomson Reuters StreetEvents
Edited Transcript of ATRA earnings conference call or presentation 8-Aug-19 12:00pm GMT
Q2 2019 Atara Biotherapeutics Inc Earnings Call
Motley FoolAtara Biotherapeutics, Inc. (ATRA) Q2 2019 Earnings Call Transcript
ATRA earnings call for the period ending June 30, 2019.
